[Post-transfusional anti-HLA hyperimmunization: importance of erythropoietin].
The use of erythropoietin (Epo) in chronic renal failure patients improves anemia and avoids iterative transfusions. As a consequence, a significant decrease of anti-HLA antibodies might be observed. From 31.12.1985 to 30.07.1991, among the 61 highly sensitized patients (pts) waiting for renal transplantation at our institution, 23 (7 men, 16 women, mean age 43.3 +/- 2.3 years) were treated with Epo during 21.4 +/- 1.7 months. After introduction of Epo, the mean number of transfusions significantly decreased from 35 +/- 8 to 0.5 +/- 0.4 (p < 0.0001) and the Panel Reactive Antibodies decreased from 88.1 +/- 1.7 to 18.8 +/- 5.6% (p < 0.0001). HLA antibodies totally disappeared in 12 patients, decreased more than 30% in 9 patients and remained stable in the 3 others. Renal transplantation was performed in 9 patients; 4 with a negative cross-match in both historical and current sera and 5 with a negative current cross-match but with a positive historical cross-match. 6/9 patients are doing well with a good graft function; 2 patients returned to hemodialysis for rejection and 1 patient died with a functioning kidney. Since Epo permits the transfusion withdrawal, its introduction in chronic renal failure treatment suppresses both the main factor of immunisation and one of the most important mechanisms of persistence of antibodies.
Mourad
G
G
Service de Néphrologie, Hôpital Lapeyronie, Montpellier.
Chong
G
G
Cristol
J P
JP
Lorho
R
R
Ramounau-Pigot
A
A
Seignalet
J
J
D000328:Adult; D000906:Antibodies / Q000097:blood; D001803:Blood Transfusion; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006680:HLA Antigens / Q000276:immunology*; D006801:Humans; D007114:Immunization; D007676:Kidney Failure, Chronic / Q000628:therapy*; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged
D000906:Antibodies; D006680:HLA Antigens; D004921:Erythropoietin
Hyperimmunisation anti-HLA post-transfusionnelle: intérêt de l'érythropoïétine.